Acquisition synergies Genpact’s acquisition of November Research Group creates a direct opportunity to cross-sell PVAI powered pharmacovigilance services by combining NRG’s SaaS capabilities with Genpact’s scalable AI and automation platform.

PVAI value prop Position PVAI as a transformational end-to-end adverse event processing solution that integrates OCR, RPA, NLP, and ML to reduce manual work, accelerate timelines, and provide real-time predictive insights for regulatory reporting and safety monitoring.

Pharma target Focus on mid-to-large biopharma and medical device manufacturers seeking scalable PV operations, since the PVAI integration can accelerate operational maturity and adherence to evolving safety regulations.

Current AI ecosystem Leverage Genpact’s existing PRIMO, PRIMO Mobile, PRIMO Regulatory, and Eureka learnings to tailor ROI-focused PV software implementations, offering a clear upgrade path for current PV customers and a faster time-to-value.

Market traction Highlight NRG’s established domain expertise and SaaS pedigree (PRIMO Mail launched) to bolster credibility with prospects seeking proven pharmacovigilance software partners and reduce sales cycle risk.